This study will start with one cohort. Two additional cohorts are under consideration and the study will be a parallel cohort expansion study.
ABN401-003 is a Phase 2 clinical study to assess efficacy, safety, tolerability and pharmacokinetic profile of ABN401 in specific populations of advance solid tumors with c-MET alterations as monotherapy.